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To characterize imaging features of pure DCIS on dynamic contrast-enhanced MR imaging (DCE-MRI), 31 consecutive patients
(37-81 years old, mean 56), including 2 Grade I, 16 Grade II, and 13 Grade III, were studied. MR images were reviewed
retrospectively and the morphological appearances and kinetic features of breast lesions were categorized according to the ACR
BI-RADS breast MRI lexicon. DCE-MRI was a sensitive imaging modality in detecting pure DCIS. MR imaging showed enhancing
lesions in 29/31 (94%) cases. Pure DCIS appeared as mass type or non-mass lesions on MRI with nearly equal frequency. The 29
MR detected lesions include 15 mass lesions (52%), and 14 lesions showing non-mass-like lesions (48%). For the mass lesions, the
most frequent presentations were irregular shape (50%), irregular margin (50%) and heterogeneous enhancement (67%). For the
non-mass-like lesions, the clumped internal enhancement pattern was the dominate feature, seen in 9/14 cases (64%). Regarding
enhancement kinetic curve, 21/29 (78%) lesions showed suspicious malignant type kinetics. No signiﬁcant diﬀerence was found in
morphology (P>. 05), tumor size (P = 0.21), and kinetic characteristics (P = .38) between non-high grade (I+II) and high-grade
(III) pure DCIS.
1.Introduction
Ductal Carcinoma In Situ (DCIS) is characterized by
proliferation of malignant cells conﬁned by the basement
membranes of ductal structures, without evidence of extra-
ductal invasion [1]. DCIS comprises diﬀerent subtypes
with heterogeneous proliferative disease processes and varies
in architecture, imaging features, and clinical outcome.
Although the progression of DCIS is not fully understood,
it is known that untreated DCIS is likely to progress to
invasive cancer within 10 years of diagnosis. Therefore, DCIS
isconsideredapreinvasiveformofinvasivebreastcancerthat
requires immediate treatment [2, 3].
With the widespread use of screening mammography,
DCISnowaccountsfor15%−20%ofallnewlydetectedbreast
cancer, with the trend still increasing [4]. In mammogra-
phy, DCIS most frequently presents as microcalciﬁcations,
accounting for about 85%−90% of diagnosed cases. An
accuratepreoperativestagingisveryimportantfortreatment
planning of DCIS. Although mammography has been the
mainstay for diagnosis of DCIS, it has limitations in deﬁning
the extension and the margin, especially in patients without
microcalciﬁcations or in those with dense breasts or breast
implants. Furthermore, there is a tendency to underestimate
the tumor size of DCIS on mammography [5–7]. Positive
surgical margin is known as an independent risk factor for
l o c a lr e c u r r e n c e[ 8–10].
Dynamic contrast-enhanced MRI (DCE-MRI) has been
proven more sensitive than mammography for detecting
breast cancer in young women with a high risk of developing2 Journal of Oncology
breast cancer [11–13]. In many instances, DCE-MRI can
reveal early stage breast cancer, including DCIS and DCIS
with small invasive carcinomas, which are mammographi-
cally, sonographically, and clinically occult. In addition to
screening, breast MR can also be used for staging purposes
to better characterize the disease extent and the presence
of multifocal multicentric lesions, which can impact on
treatment planning and the subsequent management.
Imaging characterization of patients with mixed cohort
of pure DCIS and DCIS with invasive components [14–
17] and patients with merely pure DCIS [18–25]o nD C E -
MRI has been reported before. In a study of 167 patients,
Kuhl et al. found that mammography only diagnosed 56%
pure DCIS preoperatively, while MRI achieved a diagnostic
rate of 92%. For 89 high-grade lesions, MRI detected 87
lesions (98%) while mammography only diagnosed 52% of
lesions [23]. Nevertheless, consensus regarding how MRI
can be used to aid in management of pure DCIS has not
been reached yet. Given the recent evidence that additional
diseases diagnosed by preoperative MRI often led to more
aggressive treatment yet did not improve the treatment
outcome[26,27],continuingexplorationoftheroleofbreast
MRI for the diagnosis of DCIS is needed.
The purpose of this retrospective study was to character-
izethemorphologyandenhancementkinetic patternofpure
DCIS on DCE-MRI. Since high-grade DCIS is associated
with a greater risk of local recurrence and progression to
invasive breast cancer [28–30], it would be very helpful if the
high-grade and low-grade DCIS could be diﬀerentiated on
imaging. In this paper, the MRI features of DCIS between
high-grade (Grade III) and non-high-grade (including low
Grade I and intermediate Grade II) DCIS based on the van
Nuys classiﬁcation [31] were compared.
2.MaterialsandMethods
2.1. Patients. A total of 34 consecutive patients with
histological-proven pure DCIS (without any microinvasion)
were identiﬁed from our breast MRI database collected
from 2002 to 2006. These patients came to our center to
participate in a breast MRI research study due to suspicious
lesions found in mammography, sonography, or physical
examination. The medical records, breast MRI images, and
mammogram reports (if available) were reviewed retrospec-
tively. Among these 34 patients, three patients had received
surgical excision biopsy before MR imaging, and they were
excluded in the analysis. The remaining 31 patients were
37−81 years old (mean 56). The ﬁnal diagnosis of pure DCIS
was obtained from pathological examination of mastectomy
(N = 21) and lumpectomy (N = 10) specimens. Screening
mammography reports were available for 22 patients. This
study was approved by the institutional review board, and
informed consents were obtained from all patients.
2.2. MR Imaging Protocol. The MRI study was performed
using a 1.5T Phillips Eclipse MR scanner with a standard
bilateral breast coil (Philips Medical Systems, Cleveland,
Ohio). The imaging protocol consisted of high-resolution
precontrast imaging and dynamic contrast-enhanced imag-
ing. After setting the IV line, the patient was placed into
the scanner in the prone position. The breasts were gently
cushioned inside the coil to reduce motion. The localizer
scan was ﬁrst taken to deﬁne the location of breasts. Then a
sagittal view unilateral T1-weighted precontrast images were
acquired from the breast of concern, using a spin echo pulse
sequence with TR = 1000ms, TE = 12ms, and FOV = 20cm,
and matrix size = 256 × 256. Following this, a 3D SPGR
(RF-FAST) pulse sequence with 16 frames (repetitions)
was prescribed for bilateral dynamic imaging. Thirty-two
axial slices with 4mm thickness were used to cover both
breasts. The imaging parameters were TR = 8.1ms, TE =
4.0ms, ﬂip angle = 20
◦,m a t r i xs i z e= 256 × 128, FOV =
32−38cm. The scan time was 42sec per acquisition. The
sequence was repeated 16 times for dynamic acquisitions,
fourprecontrast,and12postcontrastsets.Thecontrastagent
(Omniscan, 1cc/10lbs body weight) was manually injected
at the beginning of the 5th acquisition and was timed to
ﬁnish in 12 seconds to make the bolus length consistent for
all patients. Immediately following the contrast, 10cc saline
was injected to ﬂush in all contrast medium.
2.3. Enhancement Kinetic Time Course. All images were
transferred to a PC for analysis. The subtraction images at
1-minute postinjection were generated by subtracting the
precontrast images acquired in Frame number 3 from the
postcontrast-enhanced images acquired in Frame number 6.
The maximum intensity projections (MIPs) were also gener-
ated from the subtraction images to help identify the lesion.
The enhancement kinetic was analyzed from manually
selected ROI (Region of Interest) based on the subtraction
images at 1-minute post-injection. The enhanced tumor area
was outlined on each imaging slice covering the lesion by an
experienced breast radiologist; then a mean signal intensity
time course from all 16 time frames was obtained. The
per c entenhanc ementtimec oursewascalculat edb yﬁrstsub-
tracting the mean precontrast signal intensity (mean of ﬁrst
4 frames) from each of the subsequent 12 postcontrast signal
intensities and then normalized by the mean precontrast
signal intensity ×100%.
2.4. MR Imaging Feature Analysis. Morphological appear-
ances and enhancement kinetic features of lesions shown on
MRI were categorized according to the ACR Breast Imaging
Reporting and Data System (BI-RADS) breast MRI lexicon
[30]. The features were evaluated by 2 radiologists (with 4
and 5 years of experience in reading breast MRI) separately.
For cases with diﬀerent results, they were discussed to
reach a consensus. Based on the enhancement of lesions,
the morphology was ﬁrst separated into mass lesions and
Nonmass-like lesions. Based on the lesion size, the mass
type can be further separated into single focus/multiple
foci (<5mm) and mass (≥5mm). Then for mass lesions
other characteristics such as shape, margin, and internal
enhancement patterns were evaluated. The Nonmass-like
lesions were described by the type of enhancements (diﬀuse,
regional, segmental, focal, ductal, linear) and the internalJournal of Oncology 3
enhancement patterns (punctate/stippled, clumped, and
heterogeneous). The tumor size was measured as the longest
diameter on the maximum intensity projection (MIP) of
subtraction image.
The enhancement kinetics was divided into two phases:
the initial enhancement phase, deﬁned as enhancement
patterns within the ﬁrst 2 minutes or before the curve starts
to change, and the delayed phase, deﬁned as enhancement
pattern after 2 minutes or after the curve starts to change.
Theinitialenhancementphasewasclassiﬁedasfast,medium,
and slow. The delayed enhancement phase was described
as persistent, plateau, and washout pattern. When the
enhancement kinetics showed a rapid initial enhancement
followed by washout or reaching to a plateau in the delayed
phase, it was determined as suspicious of malignancy.
2.5. Histopathology. All cases are pure DCIS without pres-
ence of microinvasion. The pathological diagnosis was
evaluated based on the van Nuys system [29]. DCIS was
classiﬁed according to the nuclear grade (non-high grade
versus high grade) and the morphologic subtype (comedo
and noncomedo). Grade-I (low grade) and Grade-II (inter-
mediate grade) were categorized as non-high grade, and
grade-III was the high-grade.
2.6. Statistical Analysis. For statistical analysis, Fisher’s exact
test was used to examine the signiﬁcant diﬀerence between
non-high grade DCIS and high grade DCIS. A P-value <.05
was considered statistically signiﬁcant.
3. Results
3.1. Patient and Tumor Characteristics. According to the
nuclear grading system, 2 patients had Grade-I, 16 patients
had Grade-II, and 13 patients had Grade-III, all together
18 non-high grade and 13 high grade. The mean age for
non-high grade DCIS was 52 years old and 57 years old for
high-grade DCIS (P = .27). The comedo type was noted
in 12 patients (7 high grade and 5 non-high grade), and
the noncomedo type was noted in 19 patients (6 high grade
and 13 non-high grade) (Table 1). There was no signiﬁcant
diﬀerence in the histological comedo or noncomedo subtype
between the non-high grade and high grade DCIS (P>. 05).
3.2. MR Morphology Analysis
3.2.1. Tumor Size and Mass versus Nonmass Morphology.
MR imaging showed contrast-enhanced lesions in 29/31
(94%) cases. Two cases of high-grade DCIS with noncomedo
morphology were not detected by MRI and were false
negative diagnosis. The imaging features of these 29 cases are
summarized in Table 2, and 5 case examples are shown in
Figures 1−5. Among these 29 cases, mass lesions were seen in
15 cases (52%) including 12 masses and 3 focus/foci lesions
and Nonmass-like lesions in 14 cases (48%). Two cases were
multifoci (Figures 2 and 5), and the size was not measured.
Fortheremainingcases,thesizerangedfrom0.4to5cmwith
the mean of 1.9±1.2cm.Themeansizewas1.6±1.2cmfor
Table 1: Pathological types and grades of 31 pure DCIS lesions.
Grade I Grade II Grade III Total
Noncomedo type 2 11 6 19
Comedo type 0 5 7 12
Total 2 16 13 31
non-high grade DCIS and 2.2±1.3cm for high-grade DCIS,
not signiﬁcantly diﬀerent (P = .21).
For the two false negative cases, in mammography, one
casewasoccult,andtheotherwasundetermined(i.e.,needed
additional imaging evaluation). The mammographically
occult case received ultrasound exam and found a suspicious
hypoechoic mass in the left breast. After needle biopsy con-
ﬁrming malignancy, the patient received lumpectomy, and
a pure DCIS of 1.4cm was found. The mammographically
undetermined case had a palpable nodule in her left breast.
This patient was diagnosed with DCIS in the right breast 2
years ago and had already received right mastectomy. She
decided to receive left mastectomy, and a pure high grade
DCIS of 1.1cm was found.
3.2.2. Mass Lesions. Among the 15 mass lesions, 9 cases were
non-high grade, and 6 were high grade. For the 14 Nonmass-
like lesions, 9 lesions were non-high grade, and 5 cases were
high grade (P = .26). The shape, margin, and internal
enhancement patterns were evaluated in 12 mass lesions
that were ≥5mm. The most frequently seen features were
irregular shape (50%), spiculated/irregular margin (92%),
and heterogeneous enhancement (67%) (Table 3). There was
no signiﬁcant diﬀerence in the MR morphology pattern
betweenthenon-high-gradeandhigh-grademasstypeDCIS
lesions. Three case examples are shown in Figure 1 (low
grade), Figure 3 (intermediate grade), and Figure 4 (high
grade).
3.2.3. Nonmass-Like Lesions. Of 14 Nonmass lesions, 4
lesions showed regional enhancement (28%), 3 showed duc-
tal (22%), and 3 showed focal (22%) enhancements. Figure 2
shows one case example with multiple foci (intermediate
grade). Internal enhancement pattern was dominated by the
clumped pattern (Figure 5, high grade) (9/14, 64%) followed
by the heterogeneous enhancement pattern (4/14, 29%)
(Table 4).
3.3. MR Enhancement Kinetic Curve Assessment. The
enhancement kinetic curves were measured from 27 lesions.
Two Grade-II lesions had severe motion artifacts due to
patient’s movement during the delayed phase, and the
enhancement kinetic curves could not be reliably measured.
The early postcontrast subtraction images had good quality,
and the morphological features of these two lesions could
be evaluated. Twenty-one lesions (21/27, 78%) showed
the suspicious malignant type enhancement kinetics with
a rapid initial enhancement followed by plateau (Figures
1 and 5) or washout (Figures 2−4), including 1/2 Grade-I
lesion, 12/14 Grade-II lesions, and 8/11 Grade-III lesions.4 Journal of Oncology
Table 2: MR imaging features of 29 pure DCIS lesions detected by MRI.
Grade I Grade II Grade III Total %
Morphology (N = 29)
Focus/Foci (N = 3) 0 3 0 3/29 (11%)
Mass (N = 12) 1 5 6 12/29 (41%)
Nonmass (N = 14) 1 8 5 14/29 (48%)
Enhancement kinetics (N = 27)
Fast washout (N = 16) 1 8 7 16/27 (59%)
Fast plateau (N = 5) 0 4 1 5/27 (19%)
Continuous enhancement (N = 6) 1 2 3 6/27 (22%)
Table 3: Morphological characteristics of 12 mass lesions.
Grade I Grade II Grade III Total
Margin
Spiculated 0 4 1 5 (42%)
Irregular 1 1 4 6 (50%)
Smooth 0 0 1 1 (8%)
Shape
Irregular 1 2 3 6 (50%)
Lobular 0 2 1 3 (25%)
Round/Ovoid 0 1 2 3 (25%)
Internal Enhancement
Rim 0 0 1 1 (8%)
Homogenous 0 1 2 3 (25%)
Heterogeneous 1 4 3 8 (67%)
Therewas no signiﬁcantdiﬀerence of the morphology pattern for mass type
lesion between the non-high-grade (I + II) and high-grade (III) pure DCIS.
Table 4: Morphological characteristics of 14 Nonmass lesions.
Grade I Grade II Grade III Total
Enhancement Type
Diﬀuse 0 0 1 1 (7%)
Regional 1 2 1 4 (28%)
Segmental 0 1 1 2 (14%)
Focal 0 3 0 3 (22%)
Ductal 0 1 2 3 (22%)
Linear 0 1 0 1 (7%)
Enhancement Pattern
Punctate/stippled 0 0 1 1 (7%)
Clumped 1 5 3 9 (64%)
Heterogeneous 0 3 1 4 (29%)
There was no signiﬁcant diﬀerence of the morphology pattern for Nonmass
type lesion between the non-high grade (I + II) and high grade (III) pure
DCIS.
Therefore, no signiﬁcant diﬀerences were found between
enhancement kinetics of high-grade and non-high-grade
DCIS (P = .38). Among the other 8 enhanced lesions
that showed benign type enhancement kinetic curves or
undetermined kinetic curves, 6 lesions showed malignant
morphological features. Therefore, of the total 31 cases,
MRI diagnosed 27 as suspicious of malignancy, with the
sensitivity of 87% (27/31).
3.4. Correlation of MRI and Mammography Findings. Cor-
relation between screening mammogram and MR Imaging
was performed in 22 patients whose mammography reports
were available. Sixteen lesions (16/22, 73%) were classiﬁed
as BI-RADS 4 or 5, as “suspicious” or “highly suspicious
of malignancy” on mammography. Five of 22 patients were
classiﬁed as BI-RADS category 1 (normal mammogram)
and one patient as BI-RADS category-0 (need additional
imagingevaluation).OnMRI,fourof5patientswithnormal
mammogram were correctly diagnosed as suspicious of
malignancy, showing malignant type enhancement kinetics
(rapid enhancement followed by washout or plateau) and/or
the morphological appearance (irregular shape and spicu-
lated/irregular margin).
4. Discussion
Mammography may miss DCIS that does not present certain
suspiciouspatternsofmicrocalciﬁcations,andMRImayhave
a complementary role in diagnosis of these lesions. Most
of the MR imaging studies of DCIS analyzed mixed patient
cohort of pure DCIS and DCIS with invasive components.
Several studies reported the MR kinetic and morphologic
appearance of pure DCIS correlated with histopathology
ﬁndings [18–25]. In a study by Kuhl et al., only 56% pure
DCIS was detected by mammography, while MRI could
detectmorethan90%[23].Inanotherstudyof33pureDCIS
patients by Vag et al. [24] the sensitivity of mammography
and MRI was 64% and 88%, respectively. In this study, we
detected29/31(94%)enhancinglesionsanddiagnosed27/31
(87%) as suspicious of malignancy. Of the 22 patients whose
mammography reports were available, the sensitivity of
mammography was 74% (16/22). The result was comparable
to other published studies [15, 17, 19]. It was found that
most false-negative diagnosis of DCIS by MRI appeared to
be non-high-grade, noncomedo-type lesions [23, 32, 33].
In this study, we had two false negative cases of high-grade
DCISwithnoncomedomorphology.Onecaseshowedstrong
background tissue enhancements in both breasts, and the
1.4cm lesion could not be identiﬁed. The other case showed
clumped enhancement in the aﬀected breast, and the 1.1cm






























Figure 1: A 61-year-old woman with low-grade pure DCIS. Axial
precontrast T1-weighted image (top), postcontrast subtraction
image (middle), and maximum intensity projection (bottom) show
an irregular mass lesion of 1.8cm in the left breast (arrow). The
enhancement level was moderate, but clearly visible. Enhancement
kinetics demonstrates a moderate initial enhancement reaching to a
plateau.
Nuclear grade has been consistently associated with poor
prognosis and local recurrence in DCIS [26, 34–36], and
the combination of nuclear grade and comedo necrosis
was reported to correlate with the risk of local recurrence
after breast conserving surgery [34, 35]. Kuhl et al. found
that high-grade pure DCIS missed by mammography can




























Figure 2: A 55-year-old woman with intermediate-grade pure
DCIS. Axial precontrast T1-weighted image (top), postcontrast
subtraction image (middle), and maximum intensity projection
(bottom) show several foci in the right breast. Enhancement
kinetics measured from a focus lesion (arrow) demonstrates a rapid
initial enhancement followed by washout.
MRI for non-high-grade pure DCIS is also signiﬁcantly
higher than mammography [23]. In the series reported
by Vag et al. [31], all 12 mammographically occult DCIS
lesions (three low grade, four intermediate grade, ﬁve high
grade) were correctly diagnosed by MRI. In our series, 4
mammographically occult DCIS lesions were detected by































Figure 3: A 61-year-old woman with intermediate-grade pure
DCIS. Axial precontrast T1-weighted image (top), postcontrast
subtraction image (middle), and maximum intensity projection
(bottom) show a mass lesion of 2.2cm with spiculated margin in
the left breast. Enhancement kinetics demonstrates a rapid initial
enhancement followed by washout.
signiﬁcance of early detection for high-grade DCIS, this
result further strengthens the recommendation of MRI for
diagnosis of DCIS.
Pure DCIS lesions often appear as Nonmass clumped
enhancement in a regional, ductal, or linear distribution































Figure 4: A 39-year-old woman with high-grade pure DCIS. Axial
precontrast T1-weighted image (top), postcontrast subtraction
image (middle), and maximum intensity projection (bottom) show
a 2.8cm mass lesion with spiculated margin in the left breast.
Enhancement kinetics demonstrates a rapid initial enhancement
followed by washout.
of focal branching enhanced pattern on MRI for DCIS. As
the spatial resolution of MRI improves, it is anticipated
that the ductal pattern as linear or linear branching may
be seen more often, which can be a signature feature on
MRI suggesting DCIS. In our study, the typical morphologic
appearanceofpureDCISonMRIwasamass-oraNonmass-
like lesion with heterogeneous or clumped enhancement.





























Figure 5: A 47-year-old woman with high-grade pure DCIS. Axial
precontrast T1-weighted image (top), postcontrast subtraction
image (middle), and maximum intensity projection (bottom) show
aNonmass-likelesionwithductalclumpedenhancementpatternin
the right breast. Enhancement kinetics demonstrates a rapid initial
enhancement then reaching to a plateau.
lesions (52%) (Figures 3 and 4) compared to previous
publications [18, 22], the classiﬁcation of mass and Nonmass
lesions is subjective, and this may lead to variations in the
determined percentages. In the study by Viehweg et al. [34],
of the 48 enhancing pure DCIS lesions, 35 lesions (35/48,
73%) showed either well-deﬁned (N = 12) or ill-deﬁned
focal mass lesions (N = 23). The percentage will change
if some ill-deﬁned mass lesions are reclassiﬁed as Nonmass
lesions. Similar to that of Viehweg et al. [34], we did not
ﬁnd signiﬁcant diﬀerences between morphologic patterns of
high-grade and non-high-grade DCIS.
Pure DCIS does not always exhibit the typical malignant
washout kinetic curves and could show persistent and
plateau curve types [16, 18, 21, 22]. Jansen et al. reported
that the peak enhancement ratio at one minute (E1) for
pure DCIS was less than invasive cancers and more than
benign lesions [22]. Studies on the enhancement kinetic
characteristics among the diﬀerent nuclear grades of pure
DCIS did not show consistent results. Some reports have
indicated that the kinetic characteristics of low-grade pure
DCIS lesions are diﬀerent from those of intermediate- and
high-grade lesions [18, 37], whereas other studies have
revealed no diﬀerence [22, 34]. We did not ﬁnd signiﬁcant
diﬀerence between the enhancement kinetics of high-grade
and non-high-grade groups.
For the size measurement of DCIS, overall, MRI was
more trustworthy compared with mammography. Diﬀerent
local recurrence rates were found between DCIS lesions
smaller and larger than 10mm, thus an accurate size
measurement is important [38]. Boetes et al. [39] showed
a −8% deviation of MRI measured tumor size relative to
histopathologic size, compared with −29% for mammogra-
phy. Despite that in general the size measurement is more
accurate on MRI, false positive ﬁndings and tumor size over-
estimation may occur on MRI. Kumar et al. [40]r e p o r t e d
that cases in which MRI overestimated DCIS were mostly
non-high-grade and noncomedo-type lesions. The false-
positive enhancement in most cases is due to coexistence of
benign proliferative processes such as ﬁbrocystic changes or
atypical ductal hyperplasia [16, 40].
Several limitations existed in our study, including small
case number and retrospective case review. Nevertheless, the
reported cases were from consecutive patients referred to
participate in a breast MRI research study, with diagnosis of
pureDCIS;therefore,allowingobjectiveanalysisaspresented
in this study. The research study was designed to analyze the
DCE kinetics, so a protocol with a relatively high temporal
resolution (42 seconds compared to 2 minutes used in a
clinicalsetting)waschosen.Thiscouldonlybeaccomplished
by using a compromised spatial resolution, which would
inevitably aﬀect the quality of the image. However, since the
tumor size of our subjects was relatively large (1.6 ± 1.2cm
for mass lesions and 2.2 ± 1.3cm for Nonmass lesions),
we believe that the relatively low spatial resolution did not
aﬀect our ﬁndings on the analysis of lesion morphology.
The morphological features of the three focal lesions <5mm
were not evaluated. The feature about spiculated margin
might be aﬀected by the low spatial resolution, and the
percentage of lesions with spiculated margin could be higher
than the reported 42% (5/12 cases). Therefore, the cases
with spiculated and irregular margin were reported together.
Withimprovedspatialresolutionandreducedslicethickness,
it is possible that more subtle morphological features,
such as linear or linear branching rather than regional
enhancements, can be revealed for improved diagnosis of
DCIS.8 Journal of Oncology
5. Conclusion
In this retrospective analysis, the majority (94%) of pure
DCIS lesions showed contrast enhancement. MRI was more
sensitive in detecting pure DCIS compared to mammog-
raphy, hence reinforcing the role of MRI in detection and
preoperative management of pure DCIS. Most lesions (78%)
exhibited the suspicious malignant type enhancement kinet-
ics. However, we did not observe any signiﬁcant diﬀerence
in MR morphologic or kinetic features between non-high-
grade and high-grade pure DCIS. Therefore, our results did
not provide strong evidence to support the use of MRI in
staging of DCIS for treatment planning.
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